A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Verastem, Inc.
National Institutes of Health Clinical Center (CC)
Turning Point Therapeutics, Inc.
Revolution Medicines, Inc.
Merck Sharp & Dohme LLC
H. Lee Moffitt Cancer Center and Research Institute
Revolution Medicines, Inc.
DualityBio Inc.
Zhejiang Doer Biologics Co., Ltd.
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline
Revolution Medicines, Inc.
National University Hospital, Singapore
Marengo Therapeutics, Inc.
Binhui Biopharmaceutical Co., Ltd.